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Thymopentin (Arg–Lys–Asp–Val–Tyr, TP5) has shown immuno-regulatory activities in humans. In the present study, we investigated the
effects of TP5 on the proliferation and differentiation of a human promyelocyte leukemia cell line, HL-60. It is noteworthy that TP5 displayed
concentration-dependent inhibitory effects on the proliferation and colony formation of HL-60 cells. Furthermore, the decrease or even
disappearance of AgNORs from nucleoli was observed in HL-60 cells after the treatment with TP5. The suppression induced by TP5 was
accompanied by an accumulation of cell cycle in the G0/G1 phase. Moreover, TP5 significantly increased the NBT-reduction activity of HL-60
cells. Cytofluorometric and morphologic analysis indicated that TP5 had induced differentiation along the granulocytes lineage in HL-60 cells.
D-tubocurarine (TUB) significantly antagonized the inhibitory effects induced by TP5, whereas atropine did not exhibit such effect. All the
results indicated that TP5 was able to significantly inhibit proliferation and induce differentiation in HL-60 cells. Our observations also implied
that TP5 not only acted as an immunomodulatory factor in cancer chemotherapy, but is also a potential chemotherapeutic agent in the human
leukemia therapy.
© 2006 Elsevier B.V. All rights reserved.Keywords: Thymopentin; HL-60; Differentiation; Proliferation inhibition; Chemotherapeutic agent1. Introduction
A common goal of cancer therapy is the restoration of
normal growth control in transformed tissues [1]. One area that
has been intensively studied in recent years is biological
modifiers of cancer growth which are designed to retard
proliferation [2], to induce differentiation of these cells to a
quiescent, non-dividing stage [3,4], and/or to promote cell death
in malignant or pre-malignant cells [5,6]. The immortal human
myeloid leukemia cell line, HL-60, serves as an in vitro model
which has been extensively used to gain insights into the
processes of myeloid cell differentiation and their control
mechanisms. These cells are bi-potent, i.e., they can be induced
to differentiate either into granulocytes on exposure to retinoic⁎ Corresponding author. Tel.: +86 931 8912567; fax: +86 931 8912561.
E-mail address: wangrui@lzu.edu.cn (R. Wang).
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doi:10.1016/j.bbamcr.2006.07.004acid (RA) or dimethyl sulphoxide (DMSO) [7,8], or into
monocytes/macrophage-like cells with various other agents [9].
Previous observations have demonstrated that some immu-
nomodulatory peptides, like TP5 and thymosin, acted as
immunomodulatory agents in cancer chemotherapy [10,11].
Recently, our research group has observed that thymosin α1
(Tα1), a well-known immune system enhancer for the
treatment of various diseases, was able to significantly
suppress proliferation and induce apoptosis in human leukemia
cell lines [12]. TP5 comprises the amino acids (Arg–Lys–
Asp–Val–Tyr) and represents residues 32–36 of the nuclear
protein thymopoietin (TP) [13]. TP5 has been successfully
used in humans to improve immunological parameters in
neoplastic, immune deficiency and autoimmune diseases
[11,14]. It rectifies imbalances in the immune system without
observable side effects, even at very high doses. Furthermore,
TP5 also exhibits a particular value in humans with certain
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known about the effects of this immunomodulatory peptide on
the proliferation and differentiation of human promyelocyte
leukemia cells.
In the present study, the effects of TP5 on the proliferation
and differentiation of HL-60 were investigated. The anti-
proliferation and differentiation effects induced by TP5 were
determined by colony formation in soft agar, silver staining and
measuring cell viability, cell cycle phase distribution, CD11b
and CD14 cell surface antigen (markers of differentiation)
expression and NBT-reduction activity. The roles of nicotinic
acetylcholine receptors (nAChRs) and muscaric acetylcholine
receptors were also investigated.
2. Materials and methods
2.1. Chemicals
TP5 was kindly gifted by Dr. Yang of Hainan Zhonghe Pharmaceutical CO.,
LTD. (Hainan Province, China). The purity was higher than 99% (HPLC) and
the structure was determined by 1H-NMR and TOF-ESI MS. TP5 was dissolved
in sterile distilled water, and the solutions were divided into aliquots and stored
in 2 mL plastic tubes at −20 °C. The aliquots were thawed and used on the day
of the experiment.
2.2. Cells culture
HL-60 cells were cultured in RPMI-1640 medium (Gibco-BRL, USA)
supplemented with heat-inactivated 10% fetal bovine serum (Hyclon, USA),
2 mM L-glutamine, penicillin (100 IU/mL) and streptomycin (100 μg/mL). The
cells were incubated in a humidified incubator containing 5% CO2 at 37 °C.
The peripheral blood mononuclear cells (PBMCs) were isolated from human
peripheral blood. The peripheral venous blood was drawn from healthy
volunteers. Blood samples were collected into sterile bags each containing
25 μL of citrate-phosphate dextrose anticoagulant and diluted to 1:2 with
phosphate buffer saline (PBS). The PBMCs were separated by density gradient
centrifugation at 1 800 rpm for 20 min on Ficoll-Isopaque (density, 1.077 g/mL).
The isolated PBMCs were washed twice, counted by Trypan blue exclusion and
suspended in RPMI-1640 growthmedium suppliedwith 15% fetal bovine serum.
The cells were incubated in a humidified incubator containing 5% CO2 at 37 °C.
2.3. Effects of TP5 on the proliferation of HL-60 cells
HL-60 cells were plated at a density of 1×105 cells/mL, and cultured for
120h in a medium containing TP5 at various concentrations (100–800 μmol/L).
To quantify the number of cells after treatment, cells were counted at different
time points of incubation using a hemocytometer under a light microscope
(Olympus, Japan). Cell viability was determined by the Trypan blue exclusion
assay. Viability was calculated as the ratio of living cells to the total cell
population.
2.4. Effects of TP5 on the clonal proliferation of HL-60 cells in soft
agar
The Effects of TP5 on clonal proliferation of HL-60 cells were determined
by the inhibition of colony formation in soft agar. The potency of TP5 was
measured by extensive concentration–response studies. HL-60 cells were plated
into 24-well, flat-bottom plates at a density of 1×104 cells/mL using a two-layer
soft agar system with a total volume of 400 μL, as described in previous report
[1]. The feeder layer was prepared with agar (1%) that had been equilibrated to
42 °C. Prior to addition of this layer to the plate, TP5 at various concentrations
(100–800 μmol/L) was pipetted into the wells. 72 h and 96 h after incubation,
the rest of TP5 was removed from the wells, respectively. And then, after 4 days'
growth in soft agar, the colonies (≥50 cells) were counted with an invertedmicroscope (Olympus, Japan). All experiments were done at least four times in
triplicate dishes per experimental point.
2.5. Effects of TP5 on the proliferation in PBMCs
The effects of TP5 on PBMCs in vitro were determined by the cell density
and viability measured by Trypan blue exclusion assay. PBMCs were plated at a
density of 20×105 cells/mL, and cultured for 120 h in a medium containing TP5
at various concentrations (100–800 μmol/L). After staining with Trypan blue,
viable cells were counted in a microscopic counting chamber using a
hemocytometer.
2.6. Silver staining
The proliferation activity of HL-60 cells was examined by silver staining.
Quick silver staining was carried out according to the method described by
Smetana et al. [16]. 50% AgNO3 and 20% gelatin (with 1% formic acid) were
evenly mixed in a ratio of 2:1, and were then added to the newly prepared cells.
After covered with coverslips, each group of cells was incubated under safelight
condition at room temperature for 30 min. The slides were then rinsed
thoroughly in distilled water, and observed under the microscope after being
dried.
2.7. Effects of TP5 on cell cycle distribution of HL-60 cells
Effects of TP5 on cell cycle distribution were determined by flow cytometry
[17]. Exponentially proliferating cells (105 cells/well) were placed in 24-well
tissue culture plates and cultured for 4 days in RPMI-1640 medium with TP5
(100–800 μmol/L) under the same conditions as mentioned above. Control cells
were adjusted to 60–70% confluency at the time of FACS analysis. Each group
of cells was collected, washed, resuspended in PBS containing 0.2% Triton-X
and 100 μg RNase, and incubated at 37 °C for 1 h. Then the cells were washed
with PBS and then incubated with 0.5 mL of DNA-staining solution containing
propidium iodide (PI) (50 μg/mL) at 4 °C for 20 min. Cell cycle distribution was
determined on a Becton-Dickinson (Braintree, MA) FACScan Flow Cytometer
and CellFIT Cell-Cycle Analysis Software. Experiments were repeated at least
three times.
2.8. NBT-reduction assays
As a marker of cell differentiation, the reduction of NBT in HL-60 cells was
determined by a previously described method [18–20]. HL-60 cells were plated
at a density of 1×105 cells/mL, and treated with TP5 (100–800 μmol/L) for
72 h. Briefly, after each treatment, cells at a density of 1×106/mL were
incubated for 1 h in RPMI-1640 growth medium with 60 ng/mL of TPA and
0.5 mg/mL of NBT at 37 °C. Then, 2 mol/L HCl was added to each sample to
stop the reaction. After the medium was chilled on ice for 30 min, the cells were
collected and suspended in DMSO. The absorbance (OD) of the NBT reduction
product (formazane solutions) was measured at 590 nm in a kinetic microplate
reader.
2.9. Cell surface antigen expression analysis
Cells (1×105 cells/well) were placed in 24-well tissue culture plates, and
cultured for 3 days in RPMI-1640 medium with TP5 (200–800 mol/L) under the
same conditions as described above. Each group of cells was then collected and
washed with PBS. Then, the cells (1×106 cells) were re-suspended in 100 mL
diluent solution containing 1% bovine serum albumin (BSA) and 1% sodium
azide and incubated with 10 μL human monoclonal FITC conjugated CD11b
antibody (Sigma, USA) and 10 μL human monoclonal PE conjugated CD14
antibody (Sigma, USA) for 30 min at room temperature without light,
respectively. The cells were washed once with diluent solution and then fixed
in 300 μL of PBS containing 2% paraformaldehyde. Fluorescence was detected
on a Becton Dickinson FACScan™ at the excitation wavelength of 490 nm and
emission wavelength of 520 nm. Results were recorded as the mean
fluorescence index, which is the product of the % fluorescence at the mean
fluorescence intensity, with 1×104 cells being counted per treatment.
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TUB chloride (Fluka), a nAChRs antagonist, was tested at a wide range of
concentrations from 0.01 to 200 μg/mL. Atropine (The First Drug Company of
Dong-ting Lake, Hunan, China), a muscaric acetylcholine receptor antagonist,
was also investigated at a range of concentrations from 0.005 to 100 μg/mL. The
experimental procedures were consistent with those described in the literature
[21].
2.11. Statistical analysis
Results were expressed as the mean±S.E.M. Responses were analyzed with
a one-way ANOVA and Scheffe's F-test. Individual group comparisons were
made using Student's t-tests. A p<0.05 was used as the criterion for statistical
significance.Fig. 2. Photomicrographs of HL-60 cells after 72 h of incubation with
thymopentin (100–800 μmol/L) showed the concentration-dependent inhibitory
effect of thymopentin on cell proliferation. HL-60 cells were plated at a density
of 1×105 cells/mL and counted with a hemocytometer. Cell density decreased in
a concentration-dependent manner as the concentration of thymopentin is
increased from 100 to 800 μmol/L. Values for cell counts are mean±S.E.M.
There is no significantly visible change in cell morphology of HL-60 cells
treated with thymopentin (magnification ×1920).3. Results
3.1. Effects of TP5 on the proliferation in HL-60 cells
TP5 (100–800 μmol/L) caused a significant suppression
of the proliferation in HL-60 cells in a concentration-
dependent manner (Fig. 1). ED50 (50% of inhibit prolifera-
tion) values of TP5 at 48 h, 72 h and 96 h in HL-60 cells
were 490 μmol/L, 331 μmol/L and 560 μmol/L, respectively.
The anti-proliferation effect of TP5 after 72 h of incubation
displayed the most potency among those measured after
48 h, 72 h, and 96 h of incubation (compared with those of
after 48 h and 96 h incubation). Furthermore, morphological
assessment of HL-60 cultures revealed that there were no
significantly visible morphological differences between the
HL-60 cells that are treated with TP5 and the ones that are
not (Fig. 2).
3.2. Clonal inhibition of proliferation of HL-60 cells mediated
by TP5
We examined the effect of TP5 on the clonal proliferation of
HL-60 cells by inhibiting colony formation in soft agar (Fig. 3).
TP5 was able to inhibit the clonal proliferation of HL-60 cells atFig. 1. The inhibitory effect of thymopentin on the proliferation of HL-60 cells.
This effect of thymopentin against HL-60 cells in vitro was determined by the
cell density and viability using Trypan blue exclusion assay. HL-60 cells were
plated at a density of 1×105 cells/mL, and cultured for 96 h in medium
containing thymopentin at various concentrations (100–800 μmol/L). The cells
were counted with a hemocytometer. Values represent the mean±S.E.M. of data
from at least three different experiments.
Fig. 3. Concentration–response effects of thymopentin on clonal proliferation of
HL-60 cells. The effect of thymopentin on clonal proliferation of HL-60 cells
was determined by inhibiting colony formation in soft agar. HL-60 cells were
plated at a density of 1×104 cells/mL, and cultured in mediums containing
thymopentin at various concentrations (100–800 μmol/L). After 3–4 days of
growth in soft agar, the colonies (≥50 cells) were counted with an inverted
microscope. Results are expressed as the mean±S.E.M. Each point represents a
mean of data from at least four experiments with triplicate dishes. Control plates:
untreated cell.
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for TP5 at 72 h and 96 h were 404 μmol/L and 358 μmol/L,
respectively.
3.3. Effects of TP5 on the proliferation of PBMCs
We also investigated the effects of TP5 on the proliferation of
PBMCs (data not shown). TP5 displayed no inhibitory effect on
the proliferation of PBMCs within the concentration range from
100 μmol/L to 800 μmol/L. This suggested that TP5 has no
potential side effect on normal blood cells even though it
exhibited significant inhibitory effects on the proliferation of
HL-60 within the concentration range from 100 μmol/L to
800 μmol/L.
3.4. Silver reaction for proteins characteristic for interphase
AgNORs
In untreated control cells, nucleoli in silver stained cells
appeared as clusters of black particles–silver stained particles
(SSPs) in less distinct ‘nucleolar matrix’ (Fig. 4A). Numerous
silver stained particles representing silver stained nucleolus
organizer regions (AgNORs) (large arrows, Fig. 4A) were
observed in large nucleoli of nuclei in control cells. It is
noteworthy that the number of AgNORs (large arrows, Fig. 4B)
in a distinct nucleolar ‘matrix’ was reduced after treatment with
400 μmol/L TP5. Furthermore, some cells with a single SSPsFig. 4. Photomicrographs of silver stained HL-60 cells. After HL-60 cells were incu
silver staining. (A) control cells (untreated with thymopentin); (B) cells treated with 40
treated with 800 μmol/L thymopentin. The silver stained nucleolus organizer regio
arrows: numbers of AgNORs; small arrows: small single black-silver stained
(magnification×1600).(small arrows, Fig. 4B) were also observed in cells treated with
400 μmol/L TP5. After treatment with TP5 of a relatively high
concentration (600 μmol/L) for 72 h, no visible AgNORs and
only some single SSPs (small arrows, Fig. 4C) were observed in
nucleoli of HL-60 cells. Moreover, visible AgNORs and SSPs
almost disappeared in nucleoli of HL-60 cells (large thick arrow,
Fig. 4D) treated with 800 μmol/L TP5. AgNORs decreased or
disappeared from nucleoli in a concentration-dependent manner
(data not shown).
3.5. Effects of TP5 on the cell-cycle distribution of HL-60 cells
We also studied the cell-cycle distribution of HL-60 cells
after treatment with TP5 (100–700 μmol/L) for 72 h or 96 h
(Fig. 5). The percentage of HL-60 cells in the G0/G1 phase
increased from 32% (vehicle-treated cells, control group) to
44.4%, 58.7% and 60.8% after treatment with 200, 500 and
700 μmol/LTP5 for 72 h, respectively. However, the percentage
of the S phase decreased from 62.8% (control cells) to 51%,
37.8% and 36.4% after treatment with 200, 500 and 700 μmol/L
TP5 for 72 h, respectively (Fig. 5A). Similar results were also
observed after 96 h (Fig. 5B). These results indicated that TP5
could promote cell-cycle accumulation in the G0/G1 phase of
HL-60 cells. These results are consistent with the results of cell
numbers and viability assays. Therefore, the HL-60 cell growth
inhibition exerted by TP5 is probably due to the inhibition of
cellular progression to G0/G1 phases.bated with thymopentin for 72 h, their proliferation activity was determined by
0 μmol/L thymopentin; (C) cells treated with 600 μmol/L thymopentin; (D) cells
ns (AgNORs) in nucleoli of cells were observed under the microscope. Large
particles (SSPs); large thick arrow: the absence of AgNORs in nucleoli
Fig. 5. Changes of cell cycle distribution of HL-60 cells after treatment with
thymopentin. HL-60 cells were plated at a density of 1×105 cells/mL, and
cultured in mediums containing thymopentin at various concentrations (200–
800 μmol/L). After incubation, the cell cycle distribution was measured by flow
cytometry. (A) Cells treated with thymopentin for 72 h, (B) Cells treated with
thymopentin for 96 h. Control: untreated cells. Values represent the mean±S.E.
M. of data from three different experiments. *p<0.05 vs. control, **p<0.01 vs.
control.
Fig. 6. Effects of thymopentin on the differentiation of HL-60 cells were
determined by NBT-reduction. HL-60 cells were plated at a density of 1×105
cells/mL, and were treated with thymopentin (100–800 μmol/L) for 72 h.
Thymopentin significantly induced the generation of NBT-reduction activity in a
concentration-dependent manner. Values represent the mean±S.E.M. of data
from five different experiments.
Fig. 7. Cell surface antigen CD11b and CD14 expression analysis. HL-60 cells
were plated at a density of 1×105 cells/mL, and cultured for 72 h in mediums
containing thymopentin at various concentrations (200–800 μmol/L). Thymo-
pentin (200–800 μmol/L) significantly increased the number of CD11b antigen
expressing cells in a concentration-dependent manner. However, thymopentin
had weak or virtually no such potency in increasing CD14 antigen-expression
even at a concentration up to 800 μmol/L. Control: untreated cells. Values
represent the mean±S.E.M. of data from three different experiments.
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We further assessed NBT-reduction in the HL-60 cells
treated with TP5 to determine whether it induced the
differentiation of the cells (Fig. 6). Rarely were NBT positive
cells observed throughout the 72 h incubation with the
control cells. TP5 (≥500 μmol/L) significantly induced the
generation of NBT-reducing activity, and the absorbance of
the NBT reduction product (OD590nm/1×10
6 cells) increased
from 0.14 (control) to 0.58 (700 μmol/L) at 72 h. More and
more cells became NBT positive as the concentration of TP5
increased.
3.7. Effects of TP5 on the CD11b and CD14 antigens on cell-
surface
Expression of cell-surface CD11b and CD14 antigens is one
of the major differentiation markers of HL-60 cells. CD11b is a
cell surface marker for differentiation into either monocytes or
granulocytes [22]. As shown in Fig. 7, TP5 concentration-
dependently increased the number of CD11b antigen expressing
cells within a concentration range from 200 to 800 μmol/L.
However, TP5 had weak or virtually no such potency in
increasing monocytic surface CD14 antigen expression even at
a concentration up to 800 μmol/L. These findings clearlyindicated that TP5 could induce differentiation of HL-60 cells
along the granulocytes lineage.
3.8. Effects of acetylcholine receptors antagonists
TUB, a nAChRs antagonist, concentration-dependently
reduced the inhibitory effects of TP5 on the proliferation of
HL-60 (Fig. 8A), whereas atropine, a muscaric acetylcholine
receptor antagonist, did not exhibit such effects (Fig. 8B).
Furthermore, cell survival (% of control) displayed no
significant changes before and after only TUB or atropine
administration (data not shown). TUB could significantly
reduce the effects of TP5 at a high concentration (200 μg/mL).
However, TUB could only partially antagonize the effects at
relatively low concentrations (<100 μg/mL).
4. Discussion
The present investigation confirmed the effects of TP5 on the
proliferation and differentiation of human promyelocytic cell
Fig. 8. The blocking effects of TUB (A) and atropine (B) on the inhibitory effects
of TP5 on the proliferation of HL-60 cells. The cell viability was determined by
Trypan blue exclusion assays. Results are expressed as the mean±S.E.M. of 3–5
measurements. Control: cells were cultured in mediums without TP5; #p<0.01
vs. control; *p<0.05 vs. TP5-treatment groups; **p<0.01 vs. TP5-treatment
groups.
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thymus extract Thymex-L can increase the sensitivity of HL-60
cells for RA [23]. Gonser S et al. demonstrated that TP5
treatment of irradiated HL-60 cells increased the number of cells
undergoing apoptosis [24]. Recently, our research group has
observed that Tα1 was able to significantly suppress prolifera-
tion and induce apoptosis in human leukemia cell lines [12]. All
the observations mentioned above indicated that these immuno-
modulatory peptides could act on the human leukemia cells.
Our present observation confirmed the effects of TP5 on the
proliferation of HL-60 cells. The results of NBT-reducing
activity and CD11b and CD14 cell surface antigen expression
also suggested the role of TP5 on the differentiation of HL-60
cells. These results further provided direct evidence that
immunomodulatory peptides were able to significantly affect
the proliferation and differentiation of human promyelocytic
cells.
In our present investigation, TP5 caused a significant
suppression of the proliferation in HL-60 cells within a
concentration range from 100 to 800 μmol/L, but not at
relatively low concentrations (≤50 μmol/L), which was in
agreement with a previous report [23]. It has been observed that
the number of SSPs, representing AgNORs, reflects not only
the nucleolar biosynthetic activity but also the cell proliferation
[25]. In our findings, the decrease or disappearance of
AgNORs from nucleoli was observed in HL-60 cells after
treatment with TP5. The decrease or disappearance of AgNORs
represented further morphological signs of TP5 on the
proliferation of HL-60 cells. In the present study, the
suppression induced by TP5 (100–700 μmol/L, after 72 h or96 h of incubation) was accompanied by an accumulation of
cell cycle in the G0/G1 phase. However, Gonser S et al.
suggested that TP5 had no effect on the cell cycle distribution
of non-irradiated HL-60 cells at concentrations of 1 mmol/L,
3 mmol/L and 10 mmol/L after 48 h of incubation, but
increased accumulation of cells in the G2/M phase of the cell
cycle after irradiation [24]. The discrepancy between our data
and these data may be induced by differences in drug
concentration, cell density, incubation time (72 h or 96 h
versus 48h) and the situation of cells (like non-irradiated or
irradiated cells). Many factors can lead to a cell cycle
accumulation in the G0/G1 phase, like cyclin D, cyclin E1,
bcl-2, c-myc and the cyclin-dependent kinase inhibitors
(CDKIs) [1,26,27]. These cell cycle related mechanisms may
take effect in the HL-60 cell cycle accumulation induced by
TP5, however, the detailed mechanisms are largely unknown.
A common goal of cancer therapy is to restore normal
growth control in transformed tissues [1]. One area that has
been intensively studied in recent years is biological modifiers
of cancer growth which are designed to retard proliferation [2],
to induce differentiation of these cells to a quiescent, non-
dividing stage [3,4], and/or to promote cell death in malignant
or pre-malignant cells [5,6]. Cell differentiation is disrupted in
the acute leukaemia and many solid tumours. Studies of cell
differentiation in vitro have led to the postulate that this is a
consequence of uncoupling of controls that normally integrate
proliferation and cell maturation [28,29]. Whilst such
imbalances may provide a growth advantage for leukaemia
cells, cell survival is also important. Proliferation at the
expense of maturation may also allow cells to avoid apoptosis,
so that inappropriately high numbers of undifferentiated cells
are maintained [30]. In the present study, TP5 was able to
induce the differentiation of HL-60 cells along the granulo-
cytes lineage. This may provided important implications that
TP5 could act as a valuable human leukaemia therapy agent
because of its potent effects on the differentiation of human
leukaemia cells.
Recent studies have revealed that some neuronal nAChRs
mRNAs and/or proteins could be detected in non-neuronal cells
such as leukocytes. One model is based on the use of a
radiomimetic agent bleomycin on the HL-60 cell line, which is
known to be from the hematological origin and likely to express
nAChRs [31,32] together with the bcl-2 anti-apoptotic gene.
Our previous study demonstrated that TUB was able to reduce
the inhibitory effects of Tα1 on the proliferation of HL-60,
K562 and K562/ADM, but that atropine did not, indicating that
nAChRs were involved [12]. In the present study, TUB also
significantly attenuated the TP5-induced inhibitory effects on
the proliferation of HL-60, but atropine did not, indicating that
TP5 suppressed the proliferation of HL-60 via a nAChRs
mediated mechanism.
TP5 is a synthetic pentapeptide corresponding to the active
structure of the natural 49 amino acids containing thymic
hormone which has shown immunoregulatory activity in many
animal model systems and human in vitro tests [15]. A
multitude of in vivo studies have shown efficacy of TP5
treatment in the therapy of various diseases including primary
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infections etc [33]. Combined chemo-immunotherapeutical
anti-cancer treatment seems to be more efficacious than
chemotherapy alone, and the significant hematopoietic toxicity
associated with most chemotherapeutical clinical trials can be
reduced significantly by the addition of immunotherapy [10].
TP5 has recently been evaluated as an immunotherapeutic agent
for the treatment of cancer. Tumour-induced immuno-suppres-
sion leads to an imbalance within the immune system, but an
effective response is needed to eliminate residual tumour cells
after removal of the major tumour tissue by cytostatic
chemotherapy, radiation, or surgery. On the other hand,
pathogens must be eliminated in concomitant infectious
diseases. TP5-treatment led to encouraging results in malignant
diseases [11,33]. Furthermore, many observations have demon-
strated that administrations of TP5 induced positive clinical
responses in cancer patients or animal models without relevant
side effects and evident toxicity even at very high doses [10,34–
36]. Interestingly, in the present study, our results suggested that
TP5 was able to suppress the proliferation and induce
differentiation in HL-60. Furthermore, TP5 exhibited no
potential side effect on normal blood cells (like PBMCs) even
though it exhibited significant inhibitory effects on the
proliferation of HL-60. These observations implied that TP5
not only acted as an immunomodulatory factor in cancer
chemotherapy, but also had potential as a chemotherapeutic
agent in human leukemia therapy.
In conclusion, all the results indicated that TP5 was able to
significantly inhibit proliferation and induce differentiation in
HL-60 cells via a nAChRs mediated mechanism. Our observa-
tions also implied that TP5 not only acted as an immunomo-
dulatory factor in cancer chemotherapy, but also had potential as
a chemotherapeutic agent in human leukemia therapy.
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